Day: March 13, 2024

Aktia’s Annual Report 2023 published

Written by Customer Service on March 13, 2024. Posted in Public Companies.

Aktia Bank PlcStock Exchange Release13 March 2024 at 10.15 a.m. Aktia’s Annual Report 2023 published Aktia has today published its Annual Report 2023. The report is available at https://www.aktia.com/en/investors/reports-and-presentations/year/2023. The Annual Report comprises Aktia’s business review, the corporate responsibility report, the report by the Board of Directors, the financial statements for 2023, and the corporate governance report. Aktia’s non-financial report is included in the report by the Board of Directors. Aktia’s Pillar III Report 2023 and Remuneration Report 2023 for the governing bodies of Aktia Bank Plc have also been published at the same time. All documents are available on the company website www.aktia.com. The report by the Board of Directors, the financial statements, corporate governance report...

Faron’s Financial Statement Release January 1 to December 31, 2023

Written by Customer Service on March 13, 2024. Posted in Earnings Releases And Operating Results.

TURKU, Finland and BOSTON, March 13, 2024 (GLOBE NEWSWIRE) — Faron Pharmaceuticals Ltd. (“Faron” or “the Company”) (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel myeloid cell targeted immunotherapies, today announced audited full-year financial results for January 1 to December 31, 2023 (the “Period”) and provided an overview of recent corporate developments. 2023 HighlightsData from the completed Phase I part of the BEXMAB study demonstrated significant overall response rates (ORR) in both previously hypomethylating agent (HMA)-failed (5 out of 5) and higher-risk myelodysplastic syndrome (MDS) patient (5 out of 5) populations. Most responses were deep and durable with 7 out of 10 MDS patients achieving complete remission/...

The Agfa-Gevaert Group in 2023: Group EBITDA increases by 52%, powered by its growth engines – regulated information

Written by Customer Service on March 13, 2024. Posted in Public Companies.

Regulated information – March 13, 2024 – 7:45 a.m. CET The Agfa-Gevaert Group in 2023: Group EBITDA increases by 52%, powered by its growth enginesHealthCare IT:Strong improvement in profitability Continued investments in innovative solutionsDigital Print & Chemicals:Growing ZIRFON business started to contribute to profitability Profitable growth for Digital Print in spite of subdued equipment investment climate Film activities under pressure from macro-economic conditions and currency impactRadiology Solutions:Direct Radiography: Improved profitability in a soft market Medical film: Continuing impact from new centralized procurement practices in China and macro-economic and geopolitical conditionsAdjusted EBITDA at 76 million Euro: significant year-over-year...

Jeroen Spruyt appointed as President of Agfa’s Radiology Solutions division

Written by Customer Service on March 13, 2024. Posted in Public Companies.

Jeroen Spruyt appointed as President of Agfa’s Radiology Solutions division Mortsel, Belgium – March 13, 2024 – 7:45 a.m. CET Effective March 13, 2024, Jeroen Spruyt will assume the position of President of Agfa’s Radiology Solutions division. He will also join Agfa’s Executive Management Team. Jeroen Spruyt holds a degree in Applied Economics, complemented by an MBA from Vlerick Business School. Through his career in logistics and his pivotal role as co-founder and board member of TheSignalling Company, Jeroen has demonstrated exceptional leadership acumen and an entrepreneurial mindset. In September 2022, Jeroen joined the Agfa-Gevaert Group as Head of the Direct Radiography (DR) business unit, which is part of the Radiology Solutions division. He will continue to lead the DR business unit...

Solvay fourth quarter and full-year 2023 results

Written by Customer Service on March 13, 2024. Posted in Earnings Releases And Operating Results.

Press release Regulated information Solvay fourth quarter and full-year 2023 results Solid financial performance thanks to the stronger first half, and robust capital structure opening a new chapter of Solvay Brussels, March 13, 2024 – 7:00 am CET HighlightsSolvay’s FY 2023 financial statements reflect the Partial Demerger completed on December 9, 2023, with the Specialty businesses transferred to Syensqo classified as discontinued operations for 2023. New Solvay leadership team fully committed to drive the transformation of the company. Net sales for the full year 2023 at €4,880 million were down -12.6% organically versus 2022, driven primarily by volume declines. In Q4, net sales decreased organically by -18.9% from both lower volumes and prices. Underlying EBITDA of €1,246 million for the full year 2023...

Sandoz reports fourth quarter 2023 sales and full-year 2023 results

Written by Customer Service on March 13, 2024. Posted in Earnings Releases And Operating Results.

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASEStrong fourth quarter performance, with net sales1 of USD 2.5 billion, up 10% in constant currencies (up 11% in USD) Full-year 2023 net sales of USD 9.6 billion, up 7% in constant currencies (up 6% in USD) Strong growth across all three regions and double-digit growth in biosimilars both in the fourth quarter and full year Full-year 2023 core EBITDA margin of 18.1%, with strong contribution from net sales offset by expected inflation and standalone costs, and foreign exchange headwinds of 1.7 percentage points Full-year 2023 EBITDA margin of 9.5%, due to legal settlements, one-time separation costs and rationalization of specific manufacturing sites 2024 guidance of mid-single digit net sales growth in constant currencies and core EBITDA margin around...

Rubis: Rubis enters into exclusive negotiations with I Squared Capital for the sale of its 55% stake in the JV Rubis Terminal

Written by Customer Service on March 13, 2024. Posted in Mergers And Acquisitions.

Paris, 13 March 2024, 7:20am Rubis today announces it has entered into exclusive negotiations with I Squared Capital for the sale of its 55% stake in Rubis Terminal. Rubis Terminal is among the leading players in Europe in the bulk liquid storage sector with 4.0 million cubic meters storage capacity across France, Spain, and the Northern Europe hubs of Antwerp and Rotterdam. Rubis structured Rubis Terminal into a JV with I Squared (45% holding) in 2020 to implement a strategy of product diversification and geographic expansion, creating significant value for the company. By acquiring full control (100%), I Squared will seek to leverage its financial capability to further accelerate the growth and diversification of Rubis Terminal alongside the existing management team. For Rubis, this sale is the opportunity to crystalise the value...

Standard Lithium Installs Commercial DLE Column at Demonstration Plant

Written by Customer Service on March 13, 2024. Posted in Public Companies.

Further Derisks DLE Process With Testing Planned Using Full-Scale Commercial Equipment Over the Next 6 MonthsFigure 1Commercial-scale DLE column installed at Standard Lithium’s Demonstration Plant near El Dorado, Arkansas.Figure 2Barrels of Koch Engineered Solutions proprietary lithium-selective sorption currently being loaded into the commercial-scale LSS unit ahead of initial commissioning, expected in late March 2024.EL DORADO, Ark., March 13, 2024 (GLOBE NEWSWIRE) — Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV:SLI) (NYSE American:SLI) (FRA:S5L), a leading near-commercial lithium development company, is pleased to announce that it has successfully installed a commercial-scale Direct Lithium Extraction (“DLE”) column at its Demonstration Plant near El Dorado, Arkansas. The column is a LiPRO™ Lithium...

Bunker Hill Announces Equity Compensation Grants

Written by Customer Service on March 13, 2024. Posted in Public Companies.

TORONTO, March 12, 2024 (GLOBE NEWSWIRE) — Bunker Hill Mining Corp. (“Bunker Hill” or the “Company”) (TSX-V: BNKR) (OTCQB: BHLL) announces that its board of directors has approved the grant of an aggregate of 5,936,737 restricted stock units (the “RSUs”) to certain directors and officers of the Company, including its Executive Chairman, Chief Executive Officer, and Chief Financial Officer, respectively, pursuant to the terms of the Company’s amended and restated restricted stock unit incentive plan (the “RSU Plan”). The RSUs will vest in one-third increments on March 13 of 2025, 2026 and 2027 into one share of common stock of the Company (a “Common Share”) at a deemed price of C$0.11 based on the closing price of the Common Shares on the TSX Venture Exchange (the “TSX-V”) on March 12, 2024. A copy of the RSU Plan is available under...

High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization

Written by Customer Service on March 13, 2024. Posted in Public Companies.

$250,000 top award goes to Achyuta Rajaram in the nation’s oldest and most prestigious Science, Technology, Engineering and Math (STEM) competition for high school seniors TARRYTOWN, N.Y. and WASHINGTON, D.C., March 12, 2024 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Achyuta Rajaram, 17, of Exeter, NH, won the top award in the Regeneron Science Talent Search (STS) 2024, America’s oldest and most prestigious science and math competition for high school seniors. The competition, now in its 83rd year, has consistently identified young innovators who become tomorrow’s STEM leaders. The 2024 finalists demonstrated extensive scientific knowledge through research and interviews while showcasing their commitment to addressing societal issues, passion for discovery,...

Day: March 13, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice